A comprehensive view of novavax inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Novavax expects to start Phase 2 COVID-19, flu combined vaccine trial by end of 2022; initial Phase 1/2 trial data show various formulations of the combination vaccine induced immune responses in participants comparable to stand-alone shots

Novavax swings to Q1 net profit of US$203.0M from net loss of US$223.0M a year ago, with revenue up at US$704.0M from US$447.0M a year ago; company reports US$586.0M in COVID-19 vaccine sales, US$19.0M in royalties, US$99.9M in grant revenue

Jefferies: Novavax's protein-based COVID-19 vaccine Nuvaxovid could reap US$5B in global sales in 2022, as product slowly racks up green lights in EU, UK, Australia, South Korea; as pandemic becomes endemic, regular vaccination likely to be a fact of life

Novavax announces emergency use authorization for Novavax protein-based COVID-19 vaccine for adolescents aged 12 to 18 in India; vaccine is manufactured and marketed in India by Serum Institute of India under the brand Covovax

Novavax announces interim authorization in Singapore for its COVID-19 vaccine candidate

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count